BrightSpring Health (BTSG) Q2 2026 Earnings Call Transcript
BrightSpring Health Services (BTSG) reported Q2 2026 net revenue of $3.873B, up 23%, and adjusted EBITDA of $205.5M, up 44.2%, with adjusted EPS of $0.45. FY2026 guidance raised to $15.1B-$15.425B revenue and $820M-$845M adjusted EBITDA. Net debt was $1.7B (2.15x leverage).
How this was made
The 30-second read
Why it matters
Management highlighted strong top-line growth and EBITDA margin improvement, updated FY 2026 guidance, and provided a 2027 IRA impact moderation estimate. Offsetting factors include legislative headwinds and a decline in Home and Community Pharmacy revenue, plus an IRA-related EBITDA headwind.
Market read
Traders can reprice BTSG based on updated FY 2026 guidance ranges, leverage reduction, cash conversion expectations, and the quantified IRA impact path into 2027.
What to watch
Net leverage is improving, but the article also notes a $200M IRA revenue impact with a $15M EBITDA headwind and a 70% EBITDA-to-cash conversion assumption, which could diverge from realized cash generation.
Background
BrightSpring Health Services held its Q2 2026 earnings call, discussing segment performance, acquisition integration, and legislative impacts tied to the Inflation Reduction Act.
Ticker impact
BrightSpring reported Q2 results and updated FY 2026 revenue guidance to $15.1B to $15.425B, plus FY EBITDA guidance to $820M to $845M.
Near-term bias to the upside if investors focus on raised/updated growth and EBITDA margin improvement, but expect volatility around IRA impact assumptions for 2026-2027.
The article provides multiple forward-looking datapoints (FY revenue and EBITDA ranges, 2027 IRA moderation estimate, cash conversion, leverage reduction) that can re-anchor valuation and positioning, while also highlighting legislative and revenue headwinds that could temper the reaction.
Market effects
Reinforces that specialty pharmacy and infusion growth can offset legislative reimbursement pressure, keeping attention on IRA sensitivity and limited distribution drug pipeline execution.
No specific regional impact disclosed beyond national footprint and state expansion targets for infusion.
Primarily US healthcare reimbursement and specialty pharmacy dynamics; limited direct global linkage mentioned.
Counterpoint
The IRA headwind is still material in 2026, and Home and Community Pharmacy revenue is down 8% despite overall growth, so the quality of growth may be uneven across segments.
Key entities
- companyBrightSpring Health Services, Inc.
Reported Q2 2026 results and updated FY 2026 revenue and adjusted EBITDA guidance, with detailed segment drivers and IRA-related impacts.
- executiveJon Rousseau
CEO who discussed expansion plans, tuck-in M&A frequency, and IRA moderation expectations.
- executiveJennifer Phipps
CFO who provided guidance details including the estimated 2027 IRA impact moderation.
